Background and recommendations Flashcards
RTOG Rectal constraints?
V70 < 20%
V50 < 50%
RTOG Bladder constraints?
V70 < 30%
V55 < 50%
Femoral head constraints?
V55 < 2 cc
Penile bulb
Mean dose < 50 Gy
What is the dose to PTV1 for LR patients?
78 Gy at 2 Gy/fx
Contraindications to RT for prostate cancer?
- Inflammatory bowel disease
2. Scleroderma or Lupus
What imaging do you need at diagnosis?
- Bone scan if intermediate risk or higher
2. CT scan of the abdomen/pelvis if intermediate risk or higher
What are the critical elements of the PE?
- DRE with estimation of prostate size and tumor size and laterality in the prostate
What is PSA density?
- PSA value/Prostate size
What qualifies as low risk per NCCN?
T1-2a, GS 6 or less, PSA < 10
What qualifies as very low risk per NCCN?
T1c, GS 6, PSA < 10, < 3 cores+, 50% or less of any core involved with cancer, PSA density < 0.15
What qualifies as very high risk prostate cancer per NCCN?
T3b-T4
What qualifies as high risk prostate cancer per NCCN?
T3a, GS 8 or higher, PSA 20 or higher
What qualifies as intermediate risk?
T2b-T2c, GS 7, PSA 10-20
T3a
extracapsular extension
T3b
seminal vesicle invasion
T4
fixed, invades adjacent structures
T2a
Tumor involving 50% or less of one lobe
T2b
Tumor involving more than 50% of one lobe
T2c
tumor involving both lobes
T1c
Disease discovered because of elevated PSA, not evidence of prostate nodules on exam
Roach Formula for LN risk
A method of estimating postive pelvic node risk based on PSA and GS
2/3 x PSA +(10 x (GS-6))
What is the RTOG/Phoenix definitive of biochemical failure? Which patients is it applicable for?
- Nadir + 2 ng/ml = failure or any patient confirmed clinically to have recurrent prostate cancer with biopsy or treated for recurrence
- Patient s/p EBRT +/- short term ADT
ASTRO definition of biochemical failure?
3 consecutive rises in PSA; date of failure is backdated midway b/w first rise and nadir or between nadir and any rise that provokes initiation of salvage therapy; requires 2 years or more of f/u.
What is the only contraindication to RT?
- Prior RT to the pelvis
When is treatment recommended for very low risk patients by the NCCN? Is active surveillance also an option?
When the estimated survival is > 20 years
Active surveillance is an option
When is active surveillance recommended by the NCCN for patients with low risk disease?
When the estimated survival is < 10 years
What is active surveillance per the NCCN?
- PSA every 6 months
- DRE every 12 months
For patients with more than a 10 year life expectancy, a TRUS and biopsy is recommended every 12 months
What are the options for patients with intermediate risk disease and a < 10 year life expectancy?
- Active surveillance (no biopsy)
2. RT +/- short term ADT +/- brachytherapy boost
What are the options for patients with intemediate risk disease and a > 10 year life expectancy?
- Surgery +/- RT for adverse features
- Active surveillance (no biopsy)
- RT +/- short term ADT +/- brachytherapy boost
What are the options for patients with high risk cancer?
- RT + long term ADT (2-3) years
- EBRT + brachy boost+/ long term ADT (2-3 years)
- Surgery for patients without fixation +/- RT for high risk features. If LN mets then observation or ADT.